Relapsed/Refractory Acute Myeloid Leukaemia

Oncology·MeSH: Leukemia, Myeloid, Acute

5 drugs in development·2 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
olverembatinib	CHINA PHARMA HOLDINGS, INC. (CPHI)

Phase 1(2)

Drug	Company
lisaftoclax	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
olverembatinib	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)

Phase 1/Phase 2(2)

Drug	Company
reduced-dose hht	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
standard-dose hht	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)

BioSniper tracks 5 drugs in development for Relapsed/Refractory Acute Myeloid Leukaemia across 2 companies.

There are 1 clinical trial targeting Relapsed/Refractory Acute Myeloid Leukaemia tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.